Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taku Seriu

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Oncogene|October 10, 2003
Allelotype analysis in relapsed childhood acute lymphoblastic leukemiaSeisho Takeuchi, Taku Seriu, Jacques J M van Dongen, et al.
Journal of Hepatology|April 23, 2010
Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infectionOsamu Yokosuka, Koichi Takaguchi, Shinichi Fujioka, et al.
Hepatology International|November 11, 2010
Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapyTatsuya Ide, Michio Sata, Kazuaki Chayama, et al.
Hepatology International|March 23, 2010
Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis BYoshiyasu Karino, Joji Toyota, Hiromitsu Kumada, et al.
Hepatology International|August 12, 2009
Antiviral activity, dose-response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trialMichiko Shindo, Kazuaki Chayama, Satoshi Mochida, et al.
International Journal of Hematology|May 20, 2011
Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysisYukio Kobayashi, Hisashi Sakamaki, Shin Fujisawa, et al.
Cancer Science|December 22, 2005
Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphomaTakashi Watanabe, Shoji Terui, Kuniaki Itoh, et al.
Blood|May 31, 2002
Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALLMarja J Willemse, Taku Seriu, Klaudia Hettinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2005
Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphomaKensei Tobinai, Takashi Watanabe, Michinori Ogura, et al.
Leukemia & Lymphoma|August 1, 2002
Minimal residual disease in early phase of chemotherapy reflects poor outcome in children with acute lymphoblastic leukemia--a retrospective study by the Children's Cancer and Leukemia Study Group in JapanTomomi Okamoto, Shouhei Yokota, Naoyuki Katano, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Oncogene|October 10, 2003
Allelotype analysis in relapsed childhood acute lymphoblastic leukemiaSeisho Takeuchi, Taku Seriu, Jacques J M van Dongen, et al.
Journal of Hepatology|April 23, 2010
Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infectionOsamu Yokosuka, Koichi Takaguchi, Shinichi Fujioka, et al.
Hepatology International|November 11, 2010
Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapyTatsuya Ide, Michio Sata, Kazuaki Chayama, et al.
Hepatology International|March 23, 2010
Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis BYoshiyasu Karino, Joji Toyota, Hiromitsu Kumada, et al.
Hepatology International|August 12, 2009
Antiviral activity, dose-response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trialMichiko Shindo, Kazuaki Chayama, Satoshi Mochida, et al.
International Journal of Hematology|May 20, 2011
Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysisYukio Kobayashi, Hisashi Sakamaki, Shin Fujisawa, et al.
Cancer Science|December 22, 2005
Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphomaTakashi Watanabe, Shoji Terui, Kuniaki Itoh, et al.
Blood|May 31, 2002
Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALLMarja J Willemse, Taku Seriu, Klaudia Hettinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2005
Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphomaKensei Tobinai, Takashi Watanabe, Michinori Ogura, et al.
Leukemia & Lymphoma|August 1, 2002
Minimal residual disease in early phase of chemotherapy reflects poor outcome in children with acute lymphoblastic leukemia--a retrospective study by the Children's Cancer and Leukemia Study Group in JapanTomomi Okamoto, Shouhei Yokota, Naoyuki Katano, et al.
Pageof 3